D.E. Shaw & Co
ABUS icon

D.E. Shaw & Co’s Arbutus Biopharma ABUS Stock Holding History

D.E. Shaw & Co’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-30,000
Closed -$455K – 3584
2014
Q4 		$455K Hold
30,000
– – ﹤0.01% 3399
2014
Q3 		$634K Buy
+30,000
New +$490K ﹤0.01% 3157

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

D.E. Shaw & Co's ABUS Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Arbutus Biopharma (ABUS) stake by 38% in Q1 2026, selling an estimated $387K and leaving 143,201 shares worth $644K. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

D.E. Shaw & Co first reported a position in ABUS in Q3 2014 and has held it in 26 quarters since. The position peaked at $29.4M in Q1 2015. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • D.E. Shaw & Co held 143,201 shares of Arbutus Biopharma worth $644K as of Q1 2026.
  • D.E. Shaw & Co sold 88,562 Arbutus Biopharma shares in Q1 2026, an estimated $387K.
  • Arbutus Biopharma made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3717 holding.
  • D.E. Shaw & Co first reported a position in Arbutus Biopharma in Q3 2014 and has held it in 26 quarters since.
  • D.E. Shaw & Co's Arbutus Biopharma position peaked at $29.4M in Q1 2015.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.